Annual securities reports (有価証券報告書) filed on EDINET — management narrative only (statistics tables, financial-statement notes, director remuneration and cross-shareholding disclosure are excluded). TSE corporate-governance reports and TDnet are separate documents and are not read here.
Solasia Pharma K.K. 4597
| Cost of capital | no mention | matched by rule |
|---|---|---|
| PBR | no mention | matched by rule |
| Metric | no metric named | matched by rule |
| Target | no numeric target | matched by rule |
| Payout | policy language, no number 「今後、開発中の医薬品が事業化し、相当の財政状態となった際には、更なる開発投資と株主還元のバランスを重視し、配当を検討する所存です」DividendPolicyTextBlock | matched by rule |
For desks: your watchlist through these questions, kept current each filing season. Custom, from $999+.
Reply with your names